Biomarkery w diagnostyce medycznej – potencjalne zastosowania i ograniczenia

• Autorzy: Parfieniuk E. , Fornal E.
• Języki publikacji: PL

Słowa kluczowe

PL

biomarkery; diagnostyka medyczna; spektrometria mas

EN

biomarkers; medical diagnostics; mass spectrometry

• Wydawca: Roble Sp. z o.o.
• Czasopismo: LAB Laboratoria, Aparatura, Badania
• Rocznik: 2015
• Tom: R. 20, nr 3
• Strony: 29--34
• Opis fizyczny: Bibliogr. 37 poz.

Twórcy

autor

Parfieniuk E.

• Pracownia Zastosowań Metod Separacji i Spektroskopii, Interdyscyplinarne Centrum Badań Naukowych, Katolicki Uniwersytet Lubelski Jana Pawła II

autor

Fornal E.

• Pracownia Zastosowań Metod Separacji i Spektroskopii, Interdyscyplinarne Centrum Badań Naukowych, Katolicki Uniwersytet Lubelski Jana Pawła II

Bibliografia

• [1] Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 2003; 3(5): 525-529.
• [2] Mayeux R. Biomarkers: potential uses and limitation. NeuroRx 2004; 1: 182-188.
• [3] Śpiewak M, Kruk M. Biomarkery w ostrych zespołach wieńcowych. Postep Kardiol Inter 2008; 14: 183-187.
• [4] Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007; 13(4): 249-255.
• [5] Sozzi G, Cante D, Leon ME, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902-3908.
• [6] Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkes: present status and future developments. Arch Pathol Lab Med 2013; 137: 1191-1198.
• [7] Zhou X, Wang X. Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol 2014, DOI: 10.1007/s00432-014-1788-y.
• [8] Wang L, Aakre JA, Jiang R, et al. J Thorac Oncol 2010; 5: 778-785.
• [9] Hasan N, Kumar R, Kavuru MS. Lung cancer: screening beyond low-dose computed tomography: the role of novel biomarkers. Lung 2014; 192: 639-648.
• [10] Brothers JF, Hijazi K, Mascaux C, et al. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med 2013; 11: 168-182.
• [11] Hassanein M, Callison JC, Callaway-Lane C, et al. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res 2012; 5: 992-1006.
• [12] Dent AG, Sutedja TG, Zimmerman PV. Exhaled breath analysis for lung cancer. J Thorac Dis 2013; 5(S5): S540-S550.
• [13] Kałużna-Czaplińska J, Joźwik J. Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer. Trends Analyt Chem 2014; 56: 1-12.
• [14] Schmekel B, Winquis F, Vikstrom A. Analysis of breath samples for lung cancer survival. Anal Chim Acta 2014; 840: 82-86.
• [15] Publikacja World Heatlh Organization, 2012, whqlibdoc.who.int/publications/ 2012/9789241564458_ eng.pdf
• [16] Raport Alzheimer’s Association, 2014, www.alz.org
• [17] Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzehimer’s disease: a prospective cohort study. Lanset Neurol 2013; 12: 357-367.
• [18] Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056.
• [19] Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367: 795-804.
• [20] ICD-10 Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych: Rewizja dziesiąta, Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10 Opisy kliniczne i wskazówki diagnostyczne, ISBN 83-86-688-25-0, Kraków-Warszawa 2000.
• [21] Jack Jr. CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostric guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257-262.
• [22] McKhann GM, Knopman DS, Cherkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-269.
• [23] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-292.
• [24] Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impariment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-279.
• [25] Raport World Health Organization, 2014, www.alz.co.uk
• [26] Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer’s disease. Neurobiol Dis 2009; 35: 128-140.
• [27] Raport World Health Organization, 2013, www.who.int
• [28] R. Craig-Schapiro, A. M. Fagan, D.M. Holtzman, Neurobiology of Disease Vol. 35 (2009) 128-140.
• [29] Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospolipidis identify antecedent memory impairment in older adults. Nat Med 2014, DOI: 10.1038/nm.3466.
• [30] Diamant Z, Boot JD, Mantzouranis E, et al. Biomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther 2010; 23: 468-481.
• [31] Murugan A, Prys-Picard C, Calhoun WJ. Biomarkers in asthma. Curr Opin Pulm Med 2009; 15 (1): 12-18.
• [32] Fatemi F, Sadroddiny E, Gheibi A, et al. Biomolecular markers in assessment and treatment of asthma. Respirology 2014; 19: 514-523.
• [33] Zhao Y-Y, Cheng X-L, Nosratola DV, et al. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem 2014; 47:16-26.
• [34] Chen Y, Ma Z, Li A, et al. Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/ hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/ mass spectrometry. J Cancer Res Clin Oncol 2015; 141: 705-718.
• [35] Wang C, Li P, Lian A, Sun B, et al. Blood volatile compounds as biomarkers for colorectal cancer. Cancer Biol Ther 2014; 15: 200-206.
• [36] Buzatto AZ, De Sousa AC, Guedes SF, et al. Metabolomic investigation of human diseases biomarkers by CE and LC coupled to MS. Electrophoresis 2014; 1: 1-23.
• [37] Montuschi P, Santini G, Valente S, et al. Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. J Chromatogr B 2014, DOI: 10.1016/j. jchromb.2014.02.059.